Pioglitazone - Transparency Life Sciences
Alternative Names: PPAR activator (pioglitazone) - Transparency Life SciencesLatest Information Update: 15 Jan 2022
At a glance
- Originator Takeda
- Developer Transparency Life Sciences
- Class Antihyperglycaemics; Small molecules; Thiazolidinediones
- Mechanism of Action Inflammation mediator modulators; Monoamine oxidase inhibitors; Peroxisome proliferator-activated receptor gamma agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Parkinson's disease
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for research development in Parkinson's-disease in USA
- 19 Dec 2012 Early research in Parkinson's disease in USA (unspecified route)